Otsuka (United States)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. United States Food and Drug Administration美国2
2. Bristol-Myers Squibb (United States)美国2
3. AbbVie (United States)美国2
4. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas西班牙1
5. Janssen Research & Development (United States)美国1
6. Johns Hopkins University美国1
7. Sanofi (United States)美国1
8. Lundbeck (United States)美国1

按月发文

逐年被引

最新文献

1. 1
   Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse EventsDrug Safety20261
2. 2
   Teratogenic Risk Impact and Mitigation (TRIM): Study Protocol for the Development of a Decision Support Tool to Prioritize Medications for Risk MitigationDrug Safety20243
3. 3
   Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World UseDrug Safety20236
4. 4
   Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical TrialsDrug Safety202129
5. 5
   Digital medicines: clinical review on the safety of tablets with sensorsExpert Opinion on Drug Safety201854
6. 6
   Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety StudyDrug Safety201819

高被引文献

1. 1
   Digital medicines: clinical review on the safety of tablets with sensorsExpert Opinion on Drug Safety201854
2. 2
   Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical TrialsDrug Safety202129
3. 3
   Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety StudyDrug Safety201819
4. 4
   Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World UseDrug Safety20236
5. 5
   Teratogenic Risk Impact and Mitigation (TRIM): Study Protocol for the Development of a Decision Support Tool to Prioritize Medications for Risk MitigationDrug Safety20243
6. 6
   Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse EventsDrug Safety20261

主要发表期刊